A consensus statement for safety monitoring guidelines of treatments for major depressive disorder

被引：35

作者：

Dodd, Seetal ^{[1
]}

Malhi, Gin S. ^{[3
]}

Tiller, John ^{[2
]}

Schweitzer, Isaac ^{[2
]}

Hickie, Ian ^{[4
]}

Khoo, Jon Paul ^{[5
]}

Bassett, Darryl L. ^{[6
,7
]}

Lyndon, Bill ^{[3
]}

Mitchell, Philip B. ^{[8
]}

Parker, Gordon ^{[9
]}

Fitzgerald, Paul B. ^{[10
]}

Udina, Marc ^{[11
]}

Singh, Ajeet ^{[2
]}

Moylan, Steven ^{[1
]}

Giorlando, Francesco ^{[2
]}

Doughty, Carolyn ^{[12
,13
]}

Davey, Christopher G. ^{[14
]}

Theodoros, Michael ^{[15
]}

Berk, Michael ^{[1
,2
,14
,16
]}

机构：

[1] Deakin Univ, Geelong, Vic 3217, Australia

[2] Univ Melbourne, Dept Psychiat, Parkville, Vic 3052, Australia

[3] Univ Sydney, Sydney Med Sch, Discipline Psychiat, Sydney, NSW 2006, Australia

[4] Univ Sydney, Brain & Mind Res Inst, Sydney, NSW 2006, Australia

[5] Toowong Specialist Clin, Brisbane, Qld, Australia

[6] Univ W Australia, Sch Psychol & Clin Neurosci, Perth, WA, Australia

[7] Univ Notre Dame, Sch Med, Fremantle, WA, Australia

[8] Univ New S Wales, Sch Psychiat, Kensington, NSW 2033, Australia

[9] Black Dog Inst, Sydney, NSW, Australia

[10] Alfred & Monash Univ, Sch Psychol & Psychiat, Monash Alfred Psychiat Res Ctr, Melbourne, Vic, Australia

[11] Univ Barcelona, Bipolar Disorders Program, Inst Clin Neurosci, Hosp Clin,IDIBAPS,CIBERSAM, E-08007 Barcelona, Catalonia, Spain

[12] Univ Otago, Child & Family Specialty Serv, Canterbury Dist Hlth Board, Christchurch, New Zealand

[13] Univ Otago, Dept Publ Hlth & Gen Practice, Christchurch, New Zealand

[14] Orygen Youth Hlth Res Ctr, Parkville, Vic, Australia

[15] New Farm Clin, Eating Disorders Program, Brisbane, Qld, Australia

[16] Mental Hlth Res Inst, Parkville, Vic, Australia

来源：

AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY | 2011年 / 45卷 / 09期

关键词：

SEROTONIN REUPTAKE INHIBITORS; VITAMIN-D INSUFFICIENCY; EPSTEIN-BARR-VIRUS; DRUG-INTERACTIONS; MENTAL-HEALTH; INAPPROPRIATE SECRETION; PSYCHIATRIC-DISORDERS; SEVERE HYPONATREMIA; METABOLIC SYNDROME; ANXIETY DISORDERS;

D O I：

10.3109/00048674.2011.595686

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

Objective: This paper aims to present an overview of screening and safety considerations for the treatment of clinical depressive disorders and make recommendations for safety monitoring. Method: Data were sourced by a literature search using MEDLINE and a manual search of scientific journals to identify relevant articles. Draft guidelines were prepared and serially revised in an iterative manner until all co-authors gave final approval of content. Results: Screening and monitoring can detect medical causes of depression. Specific adverse effects associated with antidepressant treatments may be reduced or identified earlier by baseline screening and agent-specific monitoring after commencing treatment. Conclusion: The adoption of safety monitoring guidelines when treating clinical depression is likely to improve overall physical health status and treatment outcome. It is important to implement these guidelines in the routine management of clinical depression.

引用

页码：712 / 725

页数：14

共 173 条

[1] Mirtazapine-associated dose-dependent and asymptomatic elevation of hepatic enzymes [J].